The Scientist

» cancer, developmental biology and immunology

Most Recent

image: Image of the Day: Fish Avatars for Cancer

Image of the Day: Fish Avatars for Cancer

By | September 11, 2017

Zebrafish larvae transplanted with patients’ tumors respond as their human donors do to chemotherapy.

0 Comments

image: Study: Alcohol Industry Distorts Cancer Risk

Study: Alcohol Industry Distorts Cancer Risk

By | September 10, 2017

Researchers claim that industry groups worldwide misrepresent the carcinogenicity of alcohol products.

0 Comments

image: How Exercise Might Fight Cancer

How Exercise Might Fight Cancer

By | September 8, 2017

Epinephrine’s activation of the signaling pathway Hippo is responsible for the in vitro tumor-fighting effects of serum from women who worked out.

0 Comments

image: Booger Bacteria’s Sweet Immune Suppression

Booger Bacteria’s Sweet Immune Suppression

By | September 6, 2017

Sweet taste receptor-activating molecules produced by sinus microbes suppress the local innate immune system in humans.

1 Comment

Douglas Lowy and John Schiller, whose work led to the HPV vaccine, and Michael Hall, who discovered the TOR pathway, win this year’s prizes.

0 Comments

image: An Immunological Timeline for Pregnancy

An Immunological Timeline for Pregnancy

By | September 1, 2017

A new study uses blood samples from pregnant women to track changes in the immune system leading up to birth, and predicts gestational age from the mothers’ immune signatures.

0 Comments

image: How Immune Receptors Got into Mouse Noses

How Immune Receptors Got into Mouse Noses

By | September 1, 2017

A study traces proteins’ evolution from the immune to the olfactory system.

0 Comments

image: Do Microbes Trigger Alzheimer’s Disease?

Do Microbes Trigger Alzheimer’s Disease?

By | September 1, 2017

The once fringe idea is gaining traction among the scientific community.

6 Comments

Emerging evidence links bacterial or viral infection with the neuropathology of Alzheimer’s disease.

0 Comments

image: Gilead to Pay Nearly $12B for CAR T-Cell Company

Gilead to Pay Nearly $12B for CAR T-Cell Company

By | August 28, 2017

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

0 Comments

Popular Now

  1. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  2. Man Receives First In Vivo Gene-Editing Therapy
  3. Researchers Build a Cancer Immunotherapy Without Immune Cells
  4. Child Receives Transgenic Skin Over Most of His Body
RayBiotech